Costs and outcomes associated with clopidogrel discontinuation in Medicare beneficiaries with acute coronary syndrome in the coverage gap

Robert Lee Page II¹,² Vahram Ghushchyan¹ Richard R Allen³ Lisa Roper⁴ Don Beck⁴ Bamrom H Jonathan⁴ Feride Frech-Tamas⁵ Wing Chan⁵ R Brett McQueen¹ Kavita V Nair¹

¹School of Pharmacy, Department of Clinical Pharmacy, ²School of Medicine, Department of Physical Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, ³Peakstat Statistical Services, Evergreen, CO, ⁴Universal American, Houston, TX, ⁵Novartis Pharmaceuticals, East Hanover, New Jersey, USA

Background: Current guidelines for acute coronary syndrome recommend clopidogrel for an optimal period of 12 months in order to reduce the risk of reinfarction and mortality. Premature clopidogrel discontinuation has been associated with higher rates of rehospitalization, coronary stent thrombosis, and mortality. No data exist regarding the effect of the Medicare Part D coverage gap on medical costs and outcomes in Medicare beneficiaries who discontinue their clopidogrel upon entering the coverage gap.

Methods: Beneficiaries with a Medicare Advantage plan in 2009 who had a diagnosis of acute coronary syndrome were taking clopidogrel 75 mg daily, and reached the gap in the same year representing the study sample. From this cohort, those who filled at least two prescriptions for clopidogrel (continued) versus those that did not (discontinued) while in the gap were compared with regard to outcomes related to acute coronary syndrome and expenditure 30 days after the last prescription was filled and during any time while in the gap. Descriptive and multivariate analyses were used to compare these differences.

Results: A total of 1365 beneficiaries with acute coronary syndrome met the inclusion criteria, of which 705 beneficiaries entered into the coverage gap, wherein 103 (14.6%) and 602 (85.4%) of beneficiaries discontinued and continued clopidogrel, respectively. Compared with those who continued clopidogrel during the gap, beneficiaries who discontinued clopidogrel during the gap showed a higher trend in the number of hospitalizations related to acute coronary syndrome and emergency room visits, albeit not statistically significant. Those who discontinued clopidogrel showed a higher mean adjusted cost per member per month in hospitalizations ($3604) related to acute coronary syndrome and outpatient visits ($1144) related to acute coronary syndrome and total medical costs ($5614), albeit not statistically significant.

Conclusion: Medicare beneficiaries who face large out-of-pocket costs for clopidogrel while in the coverage gap and discontinue therapy may experience adverse events related to acute coronary syndrome.

Keywords: Medicare, acute coronary syndrome, clopidogrel, health resource utilization

Introduction

Despite advances in medical intervention and pharmacotherapy, cardiovascular disease continues to be a leading killer in the US.¹ Acute coronary syndrome (ACS) is an umbrella term that includes either unstable angina or acute myocardial infarction consisting of ST segment elevation myocardial infarction (STEMI) or non-ST segment myocardial infarction (NSTEMI). According to American Heart Association statistics, 733,000 hospital discharges in the US in 2006 were due to ACS. Approximately 80% of these cases comprised either unstable angina or NSTEMI, and about 20% were STEMI.¹ Financially, the impact of ACS is also exceedingly high, costing Americans...
more than $150 billion annually. Nearly 20% of patients with ACS are rehospitalized within one year and approximately 60% of the costs related to ACS are due to rehospitalization. Approximately one third of patients with STEMI die within 24 hours of onset of ischemia compared with 15% of patients with NSTEMI who either die or experience a reinfarction within 30 days of hospitalization.

The etiology of ACS originates from the erosion or rupture of an unstable plaque within a coronary artery, cascading to the formation of an occlusive or nonocclusive thrombus. With this in mind, the use of dual antiplatelet therapy with aspirin and a thienopyridine such as clopidogrel (Clopidogrel®), Bristol-Myers Squibb/Sanofi Pharmaceuticals, Bridgewater, NJ) has become the cornerstone of therapy in order to prevent further coronary artery reocclusion and death. On the basis of clinical trial data, the American College of Cardiology/American Heart Association recommend that medically managed patients with NSTEMI, STEMI, or unstable angina receive clopidogrel therapy for at least one month (but optimally for 12 months) and those undergoing percutaneous coronary intervention with deployment of a coronary stent independent of stent type (eg, bare metal or drug-eluting) for up to 12 months of clopidogrel after discharge. All patients with ACS should receive aspirin at the time of hospital admission and continue therapy indefinitely. Premature discontinuation of clopidogrel at any point following hospital discharge by either the patient or medical provider has been associated with higher rates of rehospitalization, coronary stent thrombosis, and mortality.

A major system-level barrier contributing to potential premature clopidogrel discontinuation has been financial constraints leading to inability to obtain the medication. Because the average age of the first ACS event is 64.5 years for men and 70.3 years for women, a large majority of these patients will rely on medication coverage through Medicare Part D. Beneficiaries who exceed their initial coverage limit, will enter into the coverage gap or the “doughnut hole” where they will be required to pay 100% of their total drug costs. The data have suggested that such a limitation on prescription benefits can disrupt drug therapy, because of high-cost prescriptions leading to poor medication adherence, with possibly adverse health outcomes and higher medical costs. To date, no study has specifically explored the impact of entering into the gap on health outcomes and costs for Medicare beneficiaries with ACS receiving clopidogrel. In this retrospective database study, we evaluated the acute effects on health resource utilization and medical costs for beneficiaries with ACS who discontinued their clopidogrel therapy compared with those who did not upon entering the coverage gap.

Materials and methods

Data source

Claims data (medical, pharmacy, and enrolment claims) for this study were obtained from Universal American, a Medicare Advantage plan serving over 200,000 Medicare beneficiaries in multiple states. The plan offers many products to Medicare beneficiaries, including health maintenance organization, preferred provider organization, and fee for service products in 2009. All products offered a pharmacy benefit, Medicare Part D plans that were similar across all products with some variations in copays levels, and generic coverage in the gap. All pharmacy benefits had an annual deductible amount of $295, followed by a four-tier plan with retail generic copays of $15, preferred brand copays of $30, non-preferred brand copays of $60, and 25% coinsurance for specialty drugs. The deductible amount, prescription copay/coinsurance, and health plan costs for medications count toward the $2700 cap. After this cap is reached, beneficiaries have entered the gap and pay 100% of their prescription costs until their out-of-pocket costs reach $4350. After this limit, members pay the greater of either 5% coinsurance or $2.40 for generics and $6.00 for brand name medications, respectively. Of the plans we examined in 2009, approximately 40% had coverage for generic medications only in the gap.

Sample selection

The study sample consisted of patients with ACS who were taking clopidogrel in the calendar year of 2009 and entered the gap at some time in 2009 (and may have left the gap as well). Beneficiaries were included in the study if they were enrolled in a Medicare Advantage Prescription Drug plan with a pharmacy benefit, were continuously enrolled for the entire calendar year of 2009, had an International Classification of Diseases, Ninth Revision code for NSTEMI/STEMI or unstable angina (410.xx, 411.1, 411.81, and 411.89) before they entered the gap, or had at least two prescriptions for clopidogrel at any time before they entered the gap.

Demographic characteristics

Characteristics of patients who reached the gap were examined for age, gender, evidence of diabetes, heart failure, hypertension, hyperlipidemia, obesity, stroke, and a prior myocardial infarction. Total comorbidity burden was also examined by the Chronic Condition Index (CCI). The
number of individuals who underwent percutaneous coronary intervention and type of coronary stent deployed were also recorded, along with the mean number of days spent in the gap.

Discontinuation of clopidogrel in the gap

Operationalization of discontinuation can be conducted in a number of ways depending on the outcomes being examined. Our goal was to examine whether ACS-related medical events occurred in the gap for those who filled at least one prescription for clopidogrel (categorized as those who continued clopidogrel use in the gap) versus those who did not (categorized as those who discontinued clopidogrel use in the gap). Because entering the gap does not fall on a specific “day” for beneficiaries, but is determined by when drug costs reach a certain threshold, some decision rules were made on the definition of entering into the gap and filling a prescription within the gap. We chose to define discontinuation for those beneficiaries who did not fill a prescription for clopidogrel when they reached the gap. These beneficiaries may have had some carryover days’ supply from a previous prescription for clopidogrel before they entered the gap but did not fill another prescription while they were in the gap. Beneficiaries were classified as continuing to take clopidogrel in the gap if they filled at least one prescription for the medication in the gap.

Utilization

Utilization was defined as ACS-related emergency room visits, hospital admissions for ACS, and need for percutaneous coronary intervention. For each of these utilization outcomes, two measures were developed. These consisted of beneficiaries who had an ACS-related emergency room visit, hospital admission, or percutaneous coronary intervention procedure within 30 days after their last prescription for clopidogrel while they were in the gap, and those who had an ACS-related emergency room visit, hospital admission, or percutaneous coronary intervention procedure at any time after their last prescription for clopidogrel while in the gap and before the end of the calendar year. The date after an ACS-related emergency room visit, hospital admission, or percutaneous coronary intervention procedure was defined as the date of the last prescription for clopidogrel plus the associated days’ supply for that prescription. The per member per month (PMPM) number of ACS-related emergency room visits, hospital admissions, and percutaneous coronary intervention procedures in the gap were also calculated for both study groups.

Expenditure

Expenditure was defined as PMPM-related expenditure in the gap for ACS-related hospitalizations and emergency room visits, hospital admissions, and total all-cause medical expenditure while in the gap. Other explanatory variables included age (as a continuous variable), gender (with males as the reference group), CCI, whether an individual had a percutaneous coronary intervention or not (as a binary variable), and number of days spent in the gap.

Statistical analysis

All outcome measures were analyzed descriptively for those patients who either continued or discontinued clopidogrel in the gap. Multivariate analysis was also used to evaluate the impact of discontinuing clopidogrel in the gap for all the outcome measures. A negative binomial regression was used to model utilization measures. A zero-adjusted negative binomial regression was used to model the less frequent measures, such as emergency room visits, while costs were modeled using generalized linear models. Both utilization measures and cost estimates were adjusted for age, CCI, clopidogrel discontinuation, female gender, percutaneous coronary intervention, and number of days in the gap. Cost data have unique statistical properties that require the use of appropriate econometric techniques. For example, cost data are strongly right-skewed and have a significant percentage of zero-cost observations in a typical aged population. To address these properties, generalized linear models with a log link were developed because this is the link function most commonly used in literature. All analysis was conducted using STATA® version 11 (College Station, TX).

Results

Using definitions based on diagnosis and clopidogrel exposure, 1365 beneficiaries with ACS met the inclusion criteria. From this cohort, 705 beneficiaries entered into the coverage gap wherein 103 beneficiaries (14.6%) discontinued clopidogrel in the gap, while the remaining 602 (85.4%) continued to have a prescription for clopidogrel in the gap.

Table 1 summarizes the demographic and clinical characteristics of the beneficiaries evaluated. For patients who discontinued and continued clopidogrel, the mean age was 70 years, with 57% of beneficiaries being male. In both groups, the majority of comorbidities which were risk factors for ACS consisted of diabetes (96%–98%), hypertension (96%–98%), hyperlipidemia (92%–95%), and previous myocardial infarction (51%–52%), with a mean CCI of 6.0. Less than 10% of patients in either group underwent percutaneous coronary
intervention, with the majority receiving drug-eluting stents. Those beneficiaries who discontinued their clopidogrel spent an average of 3.5 months in the coverage gap compared with 4.8 months for those who continued therapy ($P < 0.0001$).

Figure 1 describes the percentage of beneficiaries who had ACS-related events in the gap. More beneficiaries who discontinued clopidogrel in the gap had ACS-related hospitalizations within 30 days of discontinuation (13.6% versus 2.7%, respectively) and at any time in the gap (26.2% versus 4.7%) compared with those who continued taking clopidogrel in the gap. However, similar trends were not observed for beneficiaries undergoing percutaneous coronary intervention.

Adjusted analysis comparing the mean PMPM rates of ACS-related events showed similar trends for ACS-related hospitalizations only (Table 2). Those beneficiaries who discontinued their clopidogrel in the gap had ACS-related emergency room visits within 30 days of discontinuation (13.6% versus 2.7%, respectively) and at any time in the gap (26.2% versus 4.7%) compared with those who continued taking clopidogrel in the gap. However, similar trends were not observed for beneficiaries undergoing percutaneous coronary intervention.

### Table 1 Demographics for Medicare beneficiaries who continued or discontinued clopidogrel in the gap

<table>
<thead>
<tr>
<th></th>
<th>Discontinued clopidogrel in the gap (n = 103)</th>
<th>Continued clopidogrel in the gap (n = 602)</th>
<th>$P$ value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years, mean ± SD</td>
<td>70.47 ± 8.59</td>
<td>70.13 ± 8.18</td>
<td>0.1401</td>
</tr>
<tr>
<td>Male (%)</td>
<td>59 (57.3%)</td>
<td>342 (56.8%)</td>
<td>0.9289</td>
</tr>
<tr>
<td>Comorbidities (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diabetes</td>
<td>101 (98.1%)</td>
<td>578 (96.0%)</td>
<td>0.4067</td>
</tr>
<tr>
<td>Heart failure</td>
<td>47 (45.6%)</td>
<td>238 (39.5%)</td>
<td>0.2440</td>
</tr>
<tr>
<td>Hypertension</td>
<td>101 (98.1%)</td>
<td>581 (96.8%)</td>
<td>0.7548</td>
</tr>
<tr>
<td>Hyperlipidemia</td>
<td>98 (95.2%)</td>
<td>554 (92.0%)</td>
<td>0.2673</td>
</tr>
<tr>
<td>Obesity</td>
<td>16 (15.5%)</td>
<td>82 (13.6%)</td>
<td>0.6041</td>
</tr>
<tr>
<td>Prior MI</td>
<td>54 (52.4%)</td>
<td>308 (51.2%)</td>
<td>0.8125</td>
</tr>
<tr>
<td>Stroke</td>
<td>10 (9.7%)</td>
<td>80 (13.3%)</td>
<td>0.3143</td>
</tr>
<tr>
<td>Mean CCI ± SD</td>
<td>6.46 ± 2.08</td>
<td>6.04 ± 2.13</td>
<td>0.0688</td>
</tr>
<tr>
<td>Percutaneous coronary intervention Placement of coronary stent (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Drug-eluting stent</td>
<td>10 (9.8%)</td>
<td>54 (9.0%)</td>
<td>0.8095</td>
</tr>
<tr>
<td>Bare-metal stent</td>
<td>7 (70%)</td>
<td>40 (74%)</td>
<td></td>
</tr>
<tr>
<td>Mean time in gap ± SD (days)</td>
<td>101.74 ± 53.99</td>
<td>145.79 ± 68.49</td>
<td>&lt;0.0001</td>
</tr>
</tbody>
</table>

Abbreviations: CCI, Chronic Condition Index; MI, myocardial infarction; SD, standard deviation.

![Figure 1](https://www.dovepress.com/10.1016/j.dove.2019.05.016.s1) Percentage of Medicare beneficiaries with ACS-related medical utilization who continued or discontinued clopidogrel in the gap.

Abbreviations: ACS, acute coronary syndromes; ER, emergency room; PCI, percutaneous coronary intervention.
therapy (0.05 ± 0.1 versus 0.03 ± 0.1, respectively) and a higher rate of ACS hospitalization (adjusted incidence rate ratio [IRR] 1.42, 95% confidence interval [CI] 0.79–2.54, P = 0.24). However, none of the differences were statistically significant.

Regarding costs, beneficiaries who discontinued clopidogrel in the gap had, on average, $1109 higher costs for ACS-related hospitalizations compared with those who continued on clopidogrel (Figure 2). Emergency room costs showed a similar trend ($25 PMPM versus $9 PMPM), as did all-cause medical costs, which were $1528 higher PMPM in the gap for those who discontinued clopidogrel compared with those who continued clopidogrel in the gap. Similar results were seen in the adjusted analysis, although the differences were not statistically significant (Table 3). Compared with those who continued their clopidogrel, beneficiaries who discontinued their clopidogrel had a trend towards higher monthly medical costs in ACS rehospitalization (adjusted mean difference $3604), ACS physician visits (adjusted mean difference $1144), and total medical utilization (adjusted mean difference $5614). A minimally increased trend in emergency department visits was noted for those who discontinued therapy (adjusted mean difference $11).

**Discussion**

This is the first study to evaluate the impact of the Medicare Part D coverage gap on costs and health outcomes in Medicare beneficiaries with ACS receiving clopidogrel. Each year 2.9–3.8 million Medicare beneficiaries enter into the coverage gap with no financial assistance to pay for drugs. During the study period of 2009, the majority of Medicare drug plans (75% of stand-alone plans and 49% of Medicare Advantage plans) did not offer gap coverage during the initial coverage and the catastrophic limits. The impact of this inability to obtain medications, particularly for chronic conditions, has been shown to have a dramatic impact on medication adherence. In a recent analysis of 217,131 Medicare beneficiaries who entered into the coverage gap, Polinski et al found that beneficiaries who received no financial assistance were 18% more likely to reduce their drug adherence. Among those on cardiovascular medications, there was a 2.6-fold increased likelihood of discontinuing a branded drug compared with a 1.8-fold increased likelihood of stopping a generic medication. Zhang et al also found a 14% reduction in drug utilization among beneficiaries with no financial assistance during the coverage gap. Unfortunately, limited data exist regarding the adverse health outcomes
associated with the Medicare Part D coverage gap. In an evaluation of 2784 Medicare beneficiaries with one or more cardiovascular diagnoses, eg, hyperlipidemia, hypertension, atrial/ventricular fibrillation, or heart failure, Polinski et al found a trend of increased all-cause mortality (hazards ratio 1.27, 95% CI 0.69–2.36) and rate of ACS (hazards ratio 1.41, 95% CI 0.55–3.62).25

The findings of Zhang et al are consistent with those of our study, in that 14% of beneficiaries discontinued their clopidogrel upon entering into the gap. Similar to the findings of Polinski et al, we observed a trend towards an increase in ACS-related hospitalizations and emergency room visits. However, our small sample size did not allow for any statistical differences between the two groups to be elucidated.

We also did not find any evidence of an increased need for revascularization, and this may be due to the low number of beneficiaries who actually received a coronary stent (<10%). With this in mind, it is important to highlight that our data are more reflective of ACS patients who are using the drug for aggressive medical management rather than following percutaneous coronary intervention. Most studies evaluating the effect of premature clopidogrel discontinuation on adverse health outcomes have been performed in patients following percutaneous coronary intervention with coronary stent deployment.10,11,15 However, in the largest analysis of medically treated (ie, no percutaneous coronary intervention) patients with ACS, Ho et al evaluated the rate of all-cause mortality or acute myocardial infarction in 1568 veterans discharged with clopidogrel who discontinued therapy.12 The mean follow-up after stopping treatment was 196 ± 152 days. Death or myocardial infarction occurred in 17.1% (n = 268) of patients, with 60.8% (n = 163) of adverse events occurring 0–90 days, 21.3% (n = 27) 91–180 days, and 9.7% (n = 26) 181–270 days after stopping therapy.

ACS and all-cause expenditure also showed a trend towards higher costs for those beneficiaries who discontinued clopidogrel compared with those who did not during their stay in the gap. Once again, adjusted differences did not confirm any statistical significance between the two groups with respect to this expenditure.

In addition, while we could not specifically evaluate mortality (mortality information is incomplete in claims data), our data also suggest that premature discontinuation due to the Medicare coverage gap not only leads to increased trends in the risks for ACS rehospitalization and emergency room visits, but also has the potential to incur higher medical costs related to hospitalization, outpatient visits, and overall total medical coverage.

Finally, the health plan did institute coverage of clopidogrel for Medicare beneficiaries reaching the gap in 2010 and subsequent years. However, small sample sizes of clopidogrel users in 2010 that were independent of the study sample in 2009 did not permit a between-year comparison of coverage versus no coverage for clopidogrel users in the gap.

Our study has several of the limitations associated with observational data. First, our findings are only reflective of a single Medicare Part D plan and primarily capture outcomes and costs for patients with ACS who are receiving clopidogrel for medical treatment, not after percutaneous coronary intervention. Second, due to the small number of beneficiaries who entered into the coverage gap, the study lacked the power needed to detect significant differences between groups. However, our trends in outcomes reflect those of larger studies that have evaluated adverse outcomes upon entering the gap as well as premature clopidogrel discontinuation.12,25 Third, we could only ascertain that patients had a minimum of two months of clopidogrel exposure prior to entering the gap but less than one year. Ho et al have shown that the risk of mortality and acute myocardial infarction is highest during the first 0–90 days of stopping clopidogrel when compared with 91–180 days (adjusted IRR 1.98, 95% CI 1.46–2.69) in medically treated patients with ACS.12 In all patients with ACS receiving clopidogrel for either medical treatment or following percutaneous coronary intervention, Ho et al also found that the 0–90 day interval after stopping clopidogrel was associated with a higher risk of death and acute myocardial infarction (adjusted IRR 2.75, 95% CI 1.69–4.44) compared with the 91–360-day interval.13 These data could explain why the magnitude of our point estimates is not larger, given that some patients may have been exposed to clopidogrel for longer than 90 days. Finally, our analysis compared clopidogrel use and the related ACS outcomes of

### Table 3 Adjusted mean costs per member per month for patients who did or did not discontinue clopidogrel while in the gap

<table>
<thead>
<tr>
<th>Outcome variable</th>
<th>Adjusted mean difference*</th>
<th>P value for adjusted model</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACS hospitalization</td>
<td>$3604</td>
<td>0.33</td>
</tr>
<tr>
<td>ER visit for ACS</td>
<td>$11</td>
<td>0.70</td>
</tr>
<tr>
<td>ACS outpatient visit</td>
<td>$1144</td>
<td>0.62</td>
</tr>
<tr>
<td>Total medical costs (ACS and non-ACS)</td>
<td>$5614</td>
<td>0.47</td>
</tr>
</tbody>
</table>

**Notes:** *Difference adjusted for age, Chronic Condition Index, clopidogrel discontinuation, female gender, percutaneous coronary intervention, and number of days in the gap.

**Abbreviations:** ACS, acute coronary syndromes; ER, emergency room; PMPM, per member per month; SD, standard deviation.
those who continued the drug in the gap versus those who did not. We did not compare patterns of clopidogrel use in the groups before the members entered the gap, and we did not match the groups in our analysis due to the small sample sizes. Therefore, the groups may be inherently different in terms of adherence and other relevant characteristics.

Conclusion

The adverse clinical consequences of stopping or reducing adherence with essential evidenced-based medications can be both severe and costly. Our data add to the literature showing that Medicare beneficiaries who face large out-of-pocket costs for branded medications, such as clopidogrel, due to the coverage gap, may discontinue therapy, leading to increased health resource utilization and higher medical costs. While we only observed trends towards increases in both health resource utilization and outcome due to the coverage gap, our findings have broad clinical implications for policy and patient safety. While the Medicare Part D coverage gap is expected to close by 2020 due to the advent of health care reform, health systems should work closely with third party payers to institute comprehensive medication assistance programs for patients with conditions that warrant life-saving, evidenced-based pharmacotherapy in whom assessment of financial status is conducted at the time of hospital admission rather than at the time of discharge.

Disclosure

This study was supported by a grant from Novartis Pharmaceuticals. RLP has received funding in part through the Colorado Department of Health Policy and Financing. KVN and VG have been investigators on grants funded by Novartis Pharmaceuticals, none of which are manufacturers of clopidogrel.

References